Therapeutic strategies for cell-based neovascularization in critical limb ischemia
Samura M., Hosoyama T., Takeuchi Y., Ueno K., Morikage N., Hamano K.
Clinical Trial on Peripheral Artery Disease, published in J Transl Med (2017) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- J Transl Med (2017)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 28235425
- PMCID
- PMC5324309
- DOI
- 10.1186/s12967-017-1153-4
- Citations
- 35
Abstract (original English)
Critical limb ischemia (CLI) causes severe ischemic rest pain, ulcer, and gangrene in the lower limbs. In spite of angioplasty and surgery, CLI patients without suitable artery inflow or enough vascular bed in the lesions are often forced to undergo amputation of a major limb. Cell-based therapeutic angiogenesis has the potential to treat ischemic lesions by promoting the formation of collateral vessel networks and the vascular bed. Peripheral blood mononuclear cells and bone marrow-derived mononuclear cells are the most frequently employed cell types in CLI clinical trials. However, the clinical outcomes of cell-based therapeutic angiogenesis using these cells have not provided the promised benefits for CLI patients, reinforcing the need for novel cell-based therapeutic angiogenesis strategies to cure untreatable CLI patients. Recent studies have demonstrated the possible enhancement of therapeutic efficacy in ischemic diseases by preconditioned graft cells. Moreover, judging from past clinical trials, the identification of adequate transplant timing and responders to cell-based therapy is important for improving therapeutic outcomes in CLI patients in clinical settings. Thus, to establish cell-based therapeutic angiogenesis as one of the most promising therapeutic strategies for CLI patients, its advantages and limitations should be taken into account.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Cellular therapy for the peripheral arterial disease treatment: Protocol for a systematic review and meta-analysis
Meta-analysis on Peripheral Artery Disease, published in PLoS One (2025) — summary generated from the PubMed abstract.
- 2025
PLoS One1 citations - Level ASystematic ReviewPubMed
The Efficacy of Stem Cells in Wound Healing: A Systematic Review.
Systematic Review on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.
- 2024
Int J Mol Sci60 citations - Level AMeta-analysisEurope PMC
The Immune-Centric Revolution Translated into Clinical Application: Peripheral Blood Mononuclear Cell (PBMNC) Therapy in Diabetic Patients with No-Option Critical Limb-Threatening Ischemia (NO-CLTI)-Rationale and Meta-An
Meta-analysis on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in J Clin Med (2024) — summary generated from the PubMed abstract.
- 2024
J Clin Med2 citations - Level ASystematic ReviewEurope PMC
A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia
Systematic Review on Peripheral Artery Disease, published in J Vasc Surg (2022) — summary generated from the PubMed abstract.
- 2022
J Vasc Surg23 citations - Level AMeta-analysisEurope PMC
Autologous Stem Cell Therapy for Chronic Lower Extremity Wounds: A Meta-Analysis of Randomized Controlled Trials
Meta-analysis with a reported sample of 1096 on Peripheral Artery Disease, Chronic Wound, published in Cells (2021) — summary generated from the PubMed abstract.
- 2021
- n = 1096
Cells19 citations - Level ARandomized Controlled TrialPubMed
Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF).
Randomized Controlled Trial with a reported sample of 114 on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in Stem Cell Res Ther (2019) — summary generated from the PubMed abstract.
- 2019
- n = 114
Stem Cell Res Ther57 citations